NY-SPOTIFY-TECHNOLOGY
8.3.2019 14:07:12 CET | Business Wire | Press release
Spotify Technology S.A. (NYSE:SPOT) today announced the next step in its strategic relationship with Samsung Electronics by providing users with frictionless access to Spotify on Samsung mobile devices1 . In addition, new Spotify consumers in the U.S. with select Samsung Galaxy mobile devices, including the just-launched Galaxy S10, may qualify for six months of free Spotify Premium, redeemable in app2 . Starting on March 8, Spotify also will be pre-installed on millions of new Samsung mobile devices globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190308005233/en/
Spotify has been deeply integrated with Bixby, Samsung’s intelligence platform, designed to work across Samsung’s ecosystem of devices, Spotify also enhances the Bixby Home screen by providing Spotify content and recommendations tailored for each listener.
“We were very excited to be named Samsung’s go-to music streaming service several months ago and today’s news will only ensure a more seamless Spotify listening experience across devices for listeners around the world,” said Sten Garmark, VP of Consumer Products, Spotify. “This partnership makes it easy for Samsung mobile users to access their favorite music and podcasts on Spotify, wherever they are and however they choose to listen.”
“Our goal is to deliver the best possible mobile experience to our consumers, and Spotify is the ideal music partner to help us make that vision a reality,” said Patricio Paucar, VP of Marketing, Samsung Electronics America. “Whether they’re listening to the latest hit albums or checking out their favorite playlist, we’re giving eligible Galaxy S10 users access to an amazing six month Spotify Premium offer.”
As previously announced in August 2018, Spotify became Samsung’s go-to music service provider. Spotify will continue to support Samsung devices this year to enable Samsung and Spotify users to discover and enjoy music in new ways.
About Spotify Technology S.A.
Spotify transformed music listening forever when we launched in 2008. Our mission is to unlock the potential of human creativity by giving a million creative artists the opportunity to live off their art and billions of fans the opportunity to enjoy and be inspired by these creators. Everything we do is driven by our love for music.
Discover, manage, and share over 40 million tracks for free, or upgrade to Spotify Premium to access exclusive features including offline mode, improved sound quality, Spotify Connect and ad-free listening.
Today, we are the world’s largest music streaming subscription service with a community of 207 million users, including 96 million Spotify Premium subscribers, across 79 markets.
For more information, images, or to contact the press team, head over to our press page at https://newsroom.spotify.com/ .
1 Galaxy S10, S10+, S10e, S10 5G, Galaxy Fold and select Galaxy A series devices; may vary by region and carrier.
2 Customers can confirm eligibility via following link: spotify.com/us/legal/samsung-new-6-months-free-trial-terms-and-conditions/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190308005233/en/
Contact:
Investor Relations: Paul Vogel ir@spotify.com Or Public Relations: Dustee Jenkins press@spotify.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors9.9.2026 15:45:00 CEST | Press release
- Recognized for the invention of a bispecific antibody that transformed treatment paradigm through an unconventional approach – Recognized for realizing a novel drug discovery concept in which a bispecific antibody replaces the function of coagulation Factor VIII, which is deficient in hemophilia A. Provided improved convenience through prolonged activity and subcutaneous administration, and provided a treatment option regardless of factor VIII inhibitors, thereby helping address unmet medical needs in hemophilia A. First time since the establishment of the Lasker Foundation in 1945 that three Japanese researchers have received the award simultaneously. Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been aw
AMCS Appoints Richard Humphrey as Chief Product and Technology Officer9.9.2026 15:00:00 CEST | Press release
Industrial software executive to lead global product strategy and accelerate AI innovation AMCS, a leading technology provider for the waste and recycling industry, today announced the appointment of Richard Humphrey as Chief Product and Technology Officer. Based in Boston, Humphrey will lead the company’s global product organisation. Humphrey brings more than 25 years of experience developing software for construction and other complex industrial environments. He joins AMCS as the company deepens its focus on waste and recycling and expands the role of AI across its platform. Most recently, Humphrey served as Chief Product and Technology Officer at Contruent, where he led product strategy for a construction cost-management platform used on major capital programmes. He previously held vice president roles at Bentley Systems and B2W Software. Earlier in his career, he spent more than a decade at Autodesk, where he led its Civil Design and Construction software business as Senior Directo
BBH Launches a New Technology Business, Braid, Solving for Intelligent Data Transformation9.9.2026 14:45:00 CEST | Press release
Braid’s agentic AI platform is purpose-built for financial services firms who need to transform, connect, and manage their data with confidence Brown Brothers Harriman (BBH) today announced the launch of a new technology affiliate, Braid LLC, focused on solving enterprise data transformation for financial services. Braid offers an AI-native data transformation platform that gives firms a scale solution to transform, connect, and manage their data with confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909294398/en/ Braid empowers teams to build, automate, and oversee reliable production-grade data transformations in a fraction of the time typically required today. Instead of requiring engineers to build data automations, Braid allows business users to describe their needs in natural language that AI agents use to build intelligent data transformations that are transparent and fully auditable. Braid’s enterprise-gr
LTM Collaborates with IBM and Red Hat on Lightwell to Advance AI-Driven Open-Source Software Remediation9.9.2026 14:30:00 CEST | Press release
Strengthens software supply chains by helping enterprises transform vulnerability discovery into scalable remediation outcomes LTM, the Business Creativity partner to the world's largest enterprises, today announced that it has collaborated with IBM and Red Hat on Lightwell to help enterprises safeguard the open-source software supply chain through AI-driven vulnerability remediation. As AI accelerates the discovery of software vulnerabilities, organizations must move beyond detection-focused approaches and adopt enterprise-scale remediation strategies that enable rapid risk mitigation without disrupting business-critical applications. Lightwell’s approach of delivering validated fixes for production environments aligns with LTM's aim of helping customers build secure, resilient, and operationally efficient software supply chains. By combining AI-powered remediation capabilities with enterprise-grade validation and deployment support, Lightwell aims to help organizations address securi
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life9.9.2026 14:24:00 CEST | Press release
Data Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies Oveporexton is the First and Only Approved Orexin Agonist Designed to Treat the Underlying Cause of NT1 and is Now Approved in the U.S., China and Japan, with Additional Regulatory Submissions Underway Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1. "People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily life,” said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-86
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom